Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (โAptoseโ or the โCompanyโ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (โAptoseโ or the โCompanyโ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (โAptoseโ or the โCompanyโ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0624 | 17.7222380006 | 0.3521 | 0.4252 | 0.345 | 176137 | 0.39328483 | CS |
4 | -0.0155 | -3.60465116279 | 0.43 | 0.476 | 0.3316 | 1557214 | 0.40226011 | CS |
12 | -0.3593 | -46.43318687 | 0.7738 | 0.81 | 0.3316 | 586668 | 0.41865683 | CS |
26 | -1.0655 | -71.9932432432 | 1.48 | 1.7203 | 0.3316 | 302250 | 0.51271825 | CS |
52 | -2.9355 | -87.6268656716 | 3.35 | 3.36 | 0.3316 | 186607 | 0.82905841 | CS |
156 | -39.9355 | -98.9727385378 | 40.35 | 41.7 | 0.3316 | 335658 | 16.22702055 | CS |
260 | -35.5855 | -98.8486111111 | 36 | 138.7875 | 0.3316 | 779627 | 63.1055617 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.